慢性应激在β2肾上腺素能受体及其下游cAMP/PKA通路介导下促进肺癌进展的机制研究
结题报告
批准号:
82002440
项目类别:
青年科学基金项目
资助金额:
24.0 万元
负责人:
许仙花
依托单位:
学科分类:
肿瘤病因
结题年份:
2023
批准年份:
2020
项目状态:
已结题
项目参与者:
许仙花
国基评审专家1V1指导 中标率高出同行96.8%
结合最新热点,提供专业选题建议
深度指导申报书撰写,确保创新可行
指导项目中标800+,快速提高中标率
客服二维码
微信扫码咨询
中文摘要
肺癌患者中接近一半的病人患有抑郁症,而抑郁导致癌症死亡率增加。但目前还缺乏明确的分子机制研究来解释。在前期的细胞实验中,已证实通过调节β2-ADR/cAMP/PKA信号通路能抑制肺癌细胞的增殖。并且,我们已成功建立慢性社会挫败应激-肺癌动物模型,并初步证实慢性应激在肺癌细胞增殖、浸润及转移中起重要作用。此外,慢性应激促进肺肿瘤的增殖时,β2-ADR/cAMP/PKA信号通路的表达水平显著地增加。基于前期研究结果,本课题项目中我们将阐明β2-ADR在慢性应激促进肺癌进展中的作用,并通过调节β2-ADR观察是否可有效阻断慢性应激对肺癌进展的影响。利用基因测序筛选β2-ADR信号通路的作用靶点基因,重点阐明β2-ADR/cAMP/PKA信号通路作用机制。我们将进一步进行人体实验,探索肺癌患者的个体化差异相关基因,阐明β2-ADR/cAMP/PKA信号通路的作用机制。
英文摘要
Many cancer patients have a disorder with depression, which leads to increased the cancer mortality, but the molecular mechanism of this process is still unclear. In the previous cell experiments, we confirmed that the proliferation of lung cancer cells could be decreased by the inhibition of β2-ADR/cAMP/PKA signaling pathway. In addition, we successfully established an animal model of chronic social defeat stress-lung cancer, and preliminarily confirmed that chronic stress plays an important role in the proliferation, invasion and metastasis of lung cancer cells. Moreover, the expression levels of β2-ADR/cAMP/PKA signaling pathway were increased in lung tumors proliferation induced by chronic stress. In this study, we will explain the role of β2-ADR in promoting lung cancer progression by chronic stress, and observe whether the effect of chronic stress on lung cancer progression can be effectively blocked by regulating β2-ADR. We also plan to screen the target genes of the β2-ADR signaling pathway, and clarify an action mechanism of the β2-ADR/cAMP/PKA signaling pathway. We will conduct further human experiments to explore the individual difference of target genes in lung cancer patients, and elucidate an action mechanism of the β2-ADR /cAMP/PKA signaling pathway.
期刊论文列表
专著列表
科研奖励列表
会议论文列表
专利列表
Biphasic function of GSK3β in gefitinib‑resistant NSCLC with or without EGFR mutations.
GSK3β 在有或没有 EGFR 突变的吉非替尼耐药 NSCLC 中的双相功能。
DOI:10.3892/etm.2023.12187
发表时间:2023-10
期刊:Experimental and therapeutic medicine
影响因子:2.7
作者:Li J;Wu X;Ji XB;He C;Xu S;Xu X
通讯作者:Xu X
GSK3β/NF-κB信号轴对肺腺癌转移及EGFR-TKI耐药的作用机制
  • 批准号:
    81860414
  • 项目类别:
    地区科学基金项目
  • 资助金额:
    35.0万元
  • 批准年份:
    2018
  • 负责人:
    许仙花
  • 依托单位:
国内基金
海外基金